EMA's PRIME: Helpful But Not A Panacea
Executive Summary
European Medicines Agency will try "just as hard" to aid companies who tap into other EU regulatory tools aimed at fostering quicker reviews, official says at BIA/MHRA conference.
You may also be interested in...
First EU PRIME Designations Go To Biogen, ChemoCentryx, Kite, NovImmune
The first four drugs European Medicines Agency selects for its new priority review program include Biogen's Alzheimer's disease treatment aducanumab. Fourteen applicants did not garner PRIME status.
Many PRIME Applicants Are Missing Pediatric Investigation Plans
Aside from pediatrics research issue, most of the first batch of applications for the new priority review scheme were "in scope," with numerous therapeutic areas targeted.
EMA's New PRIME Scheme Gets 18 Applications In First Month
Eleven applications to the European priority review program came from smaller companies.